With an Investment of Over USD 1 Billion and an Intellectual Capital Spread Across ~3,000 Patents, the Encapsulated Cell Therapies and Encapsulation Technologies Market is Set to Witness a Rapid Growth, Predicts Roots Analysis - Seite 2

• Alexander Scheer (Chief Scientific Officer, Erytech Pharma)
• Manuel Pires (Business Developer, Defymed)
• Michel Revel (Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Business Development Manager, Kadimastem)
• Mick McLean (Chief Executive Officer, Atelerix)
• Quinton Oswald (Former President and Chief Executive Officer, Neurotech Pharmaceuticals)
• William L Rust (Founder and Chief Executive Officer, Seraxis)
• Yuval Avni (Former Chief Executive Officer, Beta-O2 Technologies)

The research covers detailed profiles and assesses product portfolios of several companies, including (illustrative list, no specific selection criteria):

• ALTuCELL
• Azellon Cell Therapeutics
• Beta-Cell
• Betalin Therapeutics
• CellProtect Biotechnology
• Diatranz Otsuka
• Encellin
• EryDel
• Gloriana Therapeutics
• Living Cell Technologies
• MaxiVAX
• Neurotech Pharmaceuticals
• PharmaCyte Biotech
• Semma Therapeutics
• Sernova

For additional details, please visit:
https://rootsanalysis.com/reports/view_document/cell-encapsulation-focus-on-therapeutics-and-technologies-2019-2030/249.html or email [e-mail]

Contact:
Gaurav Chaudhary
[phone]
[phone]
[e-mail]

Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg